Today: 21 May 2026
Amazon’s $200B AI spending plan jolts investors after Q4 earnings drop

Amazon’s $200B AI spending plan jolts investors after Q4 earnings drop

New York, Feb 5, 2026, 16:12 EST

  • Amazon projects roughly $200 billion in capital spending by 2026, doubling down on its AI expansion
  • Shares dropped almost 8% in after-hours trading following first-quarter operating income guidance that missed expectations
  • Fourth-quarter sales jumped 14%, and AWS growth picked up speed, though free cash flow dropped due to increased investment

Amazon.com expects to spend around $200 billion on capital expenditures in 2026. Its shares dropped nearly 8% in after-hours trading Thursday, after the company’s profit forecast for the first quarter came in below Wall Street expectations. Amazon projected operating income between $16.5 billion and $21.5 billion, falling short of analysts’ $22.04 billion estimate, according to LSEG data compiled by Reuters.

Spending size is a key focus as markets grow wary of Big Tech’s AI expenses. U.S. stocks tumbled on Thursday, with the Nasdaq hitting its lowest point since November. Investors are uneasy over the timeline for AI investments to boost earnings.

Amazon’s fourth-quarter net sales hit $213.4 billion, marking a 14% increase from last year. AWS, the cloud division, saw revenue climb 24% to $35.6 billion. Operating income rose to $25.0 billion. However, free cash flow over the past 12 months dipped to $11.2 billion, weighed down by higher spending on property and equipment. The company attributed this mainly to “investments in artificial intelligence.” CEO Andy Jassy revealed plans to pour about $200 billion into capex by 2026, highlighting key areas like AI, chips, robotics, and low earth orbit satellites. Business Wire

Capital expenditures, or capex, refer to funds companies invest in long-lived assets like data centers, chips, and networking equipment. While these outlays can drive future growth, they often squeeze cash flow in the short run, testing investors’ patience.

Before the release, Bloomberg consensus estimates viewed by Business Insider put fourth-quarter revenue around $211.5 billion, with AWS sales close to $34.9 billion. “This expenditure will loom large” on Amazon’s full-year earnings, Lee Sustar, a vice president and principal analyst at Forrester, told Business Insider, referring to the company’s spending plans. Business Insider

Wedbush analysts, as reported by Proactive Investors, stuck with their “Outperform” rating and set a $340 price target ahead of the earnings release. They noted that “investor confidence has been building” following a strong AWS showing last quarter. Key drivers for the stock in 2026, they said, will be AWS momentum, growth in advertising, and the scale of capital expenditures. Proactiveinvestors NA

This week, a Motley Fool column spotlighted Amazon as a key AI player, pointing to strong AWS demand, its partnership and investment in AI firm Anthropic, and the in-house development of Trainium chips. Out of 74 analyst ratings tracked by MarketWatch, 60 tagged the stock as a buy.

Amazon faces a familiar squeeze: it must invest heavily in cloud and AI capacity while proving those costs boost margins and cash flow. The company’s figures highlight this balancing act — AWS growth is picking up, but free cash flow is slipping.

The downside is straightforward. If AI workload demand dips or customers continue cutting budgets while Amazon faces higher depreciation from fresh investments, profits could suffer longer than investors expect. A fiercer price war in cloud or retail would only add pressure.

Investors are eager to see just how quickly AWS can ramp up capacity, what share of that $200 billion budget goes to AI infrastructure, and how fast Amazon can convert this spending spree into steady cash flow.

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
S&P Global stock slides again as “Mobility Global” spin-off rebrand puts SPGI in the spotlight
Previous Story

S&P Global stock slides again as “Mobility Global” spin-off rebrand puts SPGI in the spotlight

AppLovin stock price slips after hours as CloudX launch and Wedbush target cut put Feb. 11 earnings in play
Next Story

AppLovin stock price slips after hours as CloudX launch and Wedbush target cut put Feb. 11 earnings in play

Go toTop